Rabbit anti-Human ITM2B Polyclonal Antibody, FITC conjugated

Uniprot Id

Q9Y287

Target Species

Human

Target Name

ITM2B

Target Full Name

Integral membrane protein 2B

Target Function

Plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites.; Mature BRI2 (mBRI2) functions as a modulator of the amyloid-beta A4 precursor protein (APP) processing leading to a strong reduction in the secretion of secretase-processed amyloid-beta protein 40 and amyloid-beta protein 42.; Bri23 peptide prevents aggregation of APP amyloid-beta protein 42 into toxic oligomers.

Target Involvement

Cerebral amyloid angiopathy, ITM2B-related 1 (CAA-ITM2B1); Cerebral amyloid angiopathy, ITM2B-related 2 (CAA-ITM2B2); Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities (RDGCA)

Target Subcellular Location

[Integral membrane protein 2B]: Golgi apparatus membrane; Single-pass type II membrane protein.; [Bri23 peptide]: Secreted.; [BRI2C, soluble form]: Secreted.

Target Protein Families

ITM2 family

Target Tissue Specificity

Ubiquitous. Expressed in brain.

Target Synonyms

ABRI; ABri/ADan amyloid peptide; BRI 2; BRI; BRI2; BRICD 2B; BRICD2B; BRICHOS domain containing 2B; E25B; E3 16; E3-16; FBD; imBRI2; Immature BRI2; Integral membrane protein 2B; ITM 2B; ITM2B; ITM2B_HUMAN; Protein E25B; RDGCA; Transmembrane protein BRI

Target Background

Amyloid precursor proteins are processed by beta-secretase and gamma-secretase to produce beta-amyloid peptides which form the characteristic plaques of Alzheimer disease. This gene encodes a transmembrane protein which is processed at the C-terminus by furin or furin-like proteases to produce a small secreted peptide which inhibits the deposition of beta-amyloid. Mutations which result in extension of the C-terminal end of the encoded protein, thereby increasing the size of the secreted peptide, are associated with two neurogenerative diseases, familial British dementia and familial Danish dementia.